-
Mashup Score: 3Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers - 11 month(s) ago
The standard-of-care (SOC) for genomic testing of myeloid cancers primarily relies on karyotyping/fluorescent in situ hybridization (FISH) (cytogenetic analysis) and targeted gene panels (usually ≤54 genes) that harbor hotspot pathogenic variants (molecular genetic analysis). Despite this combinatorial approach, ~50% of myeloid cancer genomes remain cytogenetically normal, and the limited…
Source: MDPICategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
Acute myeloid leukemia (AML) is a devastating disease. Intensive chemotherapy is the mainstay of treatment but results in debilitating toxicities. Moreover, many treated patients will eventually require hematopoietic stem cell transplantation (HSCT) for disease control, which is the only potentially curative but challenging option. Ultimately, a subset of patients will relapse or have refractory…
Source: MDPICategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Cancers - 11 month(s) ago
Cancers, an international, peer-reviewed Open Access journal.
Source: www.mdpi.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0CAR-T Cells Immunotherapies for the Treatment of Acute Myeloid Leukemia—Recent Advances - 12 month(s) ago
In order to increase the effectiveness of cancer therapies and extend the long-term survival of patients, more and more often, in addition to standard treatment, oncological patients receive also targeted therapy, i.e., CAR-T cells. These cells express a chimeric receptor (CAR) that specifically binds an antigen present on tumor cells, resulting in tumor cell lysis. The use of CAR-T cells in the…
Source: MDPICategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Novel Investigational Agents and Pathways That May Influence the Future Management of Acute Myeloid Leukemia - 12 month(s) ago
Acute Myeloid leukemia (AML) is a clinically heterogeneous disease with a 5-year overall survival of 32% between 2012 to 2018. The above number severely dwindles with age and adverse risk of disease, presenting opportunities for new drug development and is an area of dire unmet need. Basic science and clinical investigators across the world have been working on many new and old molecule…
Source: MDPICategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma: So Many Options, How to Choose? - 12 month(s) ago
The treatment landscape for relapsed/refractory classical Hodgkin’s lymphoma (cHL) has evolved with the introduction of several novel agents. Historically, the standard of care for relapsed cHL was salvage chemotherapy followed by autologous stem cell transplant (ASCT). However, many patients are ineligible for ASCT or will have poor responses to salvage chemotherapy and ASCT. Brentuximab vedotin…
Source: MDPICategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Blinatumomab in Relapsed/Refractory Burkitt Lymphoma - 12 month(s) ago
In patients with relapsed/refractory Burkitt lymphoma (r/r BL), overall survival (OS) is poor, and effective therapies and evidence for the best therapy are lacking. The monoclonal antibody blinatumomab may represent a novel option. However, only limited data on the use of blinatumomab in r/r BL are so far available. This multi-center, retrospective case series investigated nine patients with r/r…
Source: MDPICategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 5The Black Hole: CAR T Cell Therapy in AML - 12 month(s) ago
Despite exhaustive studies, researchers have made little progress in the field of adoptive cellular therapies for relapsed/refractory acute myeloid leukemia (AML), unlike the notable uptake for B cell malignancies. Various single antigen-targeting chimeric antigen receptor (CAR) T cell Phase I trials have been established worldwide and have recruited approximately 100 patients. The high…
Source: MDPICategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Progress toward Better Treatment of Therapy-Related AML - 12 month(s) ago
Therapy-related acute myeloid leukemia (t-AML) comprises 10–20% of all newly diagnosed cases of AML and is related to previous use of chemotherapy or ionizing radiotherapy for an unrelated malignant non-myeloid disorder or autoimmune disease. Classic examples include alkylating agents and topoisomerase II inhibitors, whereas newer targeted therapies such as poly (adenosine diphosphate–ribose)…
Source: MDPICategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 7Molecularly Targeted Therapy in Acute Myeloid Leukemia: Current Treatment Landscape and Mechanisms of Response and Resistance - 12 month(s) ago
Treatment for acute myeloid leukemia (AML) has evolved rapidly over the last decade as improved understanding of cytogenetic and molecular drivers of leukemogenesis refined survival prognostication and enabled development of targeted therapeutics. Molecularly targeted therapies are now approved for the treatment of FLT3 and IDH1/2-mutated AML and additional molecularly and cellularly targeted…
Source: MDPICategories: Hem/Oncs, Latest HeadlinesTweet
Our recent publication using Optical Genome Mapping & NGS for myeloid malignancies from #RaviKolhe and team @GACancerCenter. https://t.co/4PeLt48ZHW #mdpicancers via @Cancers_MDPI